Botanix Pharmaceuticals Ltd (ASX: BOT) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Botanix Pharmaceuticals Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $281.42 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 1.56 billion
Earnings per share -0.008
Dividend per share N/A
Year To Date Return -7.89%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Botanix Pharmaceuticals Ltd (ASX: BOT)
    Latest News

    a woman
    Share Fallers

    Why Botanix, Elixinol Global, Pro Medicus, & Tinybeans shares tumbled lower

    The Botanix Pharmaceuticals Ltd (ASX:BOT) share price and the Pro Medicus Limited (ASX:PME) share price are two of four tumbling…

    Read more »

    a woman
    Share Fallers

    Why the Botanix share price could crash lower on Wednesday

    The Botanix Pharmaceuticals Ltd (ASX:BOT) share price looks set to crash lower on Wednesday following a disappointing study result...

    Read more »

    a woman
    Share Market News

    Should you still be invested in ASX marijuana shares?

    With the main ASX marijuana stocks currently hanging around 52-week lows, is there still room for them in your portfolio?

    Read more »

    a woman
    Share Market News

    Why the Botanix share price is sagging today

    The Botanix Pharmaceuticals Ltd (ASX: BOT) share price is falling after two ASX annoucements

    Read more »

    a woman
    Share Gainers

    Why Bellamy's, Botanix, Objective Corp, & St Barbara shares charged higher today

    The Bellamy's Australia Ltd (ASX:BAL) share price and the Botanix Pharmaceuticals Ltd (ASX:BOT) share price are two of four racing…

    Read more »

    a woman
    Share Gainers

    Why cannabis company Botanix rocketed higher today

    The Botanix Pharmaceuticals Ltd (ASX:BOT) share price has been on fire again on Monday. Here's why...

    Read more »

    a woman
    52-Week Highs

    Why Jumbo Interactive and these exciting ASX shares just stormed to 52-week highs

    The Jumbo Interactive Ltd (ASX:JIN) share price is one of three that reached 52 week highs or better on Tuesday. Here's why...

    Read more »

    a woman
    Share Gainers

    These ASX cannabis shares have smoked the market in 2019

    The Althea Group Holdings Ltd (ASX:AGH) share price and the Botanix Pharmaceuticals Ltd (ASX:BOT) share price have smoked the market in 2019. Here's…

    Read more »

    a woman
    Share Gainers

    Why cannabinoid company Botanix rocketed 25% higher today

    The Botanix Pharmaceuticals Ltd (ASX:BOT) share price has been storming higher on Thursday. Here's why the cannabis company is on…

    Read more »

    a woman
    Share Gainers

    Why these ASX cannabis shares surged higher today

    The Botanix Pharmaceuticals Ltd (ASX:BOT) share price and the MGC Pharmaceuticals Ltd (ASX:MXC) share price have surged higher on Wednesday.…

    Read more »

    a woman
    Share Market News

    ASX small-cap AusCann Group ramps up cannabis research

    Cannabis-related research and development is booming at the moment as companies rush to capitalise on its gradual legalisation.

    Read more »

    a woman
    Share Gainers

    These 3 small cap ASX shares are surging higher today

    The DigitalX Ltd (ASX:DCC) share price is one of three surging higher at the small end of the market on…

    Read more »

    BOT ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Botanix Pharmaceuticals Ltd

    Botanix Pharmaceuticals Ltd is a clinical-stage cannabinoid therapeutics company. The company's focus is the development of safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietarydrug delivery system - Permetrex for direct skin delivery of active pharmaceuticals in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1308 - Plaque Psoriasis, BTX1204 - Atopic Dermatitis, and BTX 1701 - Mild Acne. The majority of Revenue is Derived from Australia.

    BOT Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    01 Mar 2024 $0.18 $0.01 5.88% 1,129,752 $0.18 $0.18 $0.17
    29 Feb 2024 $0.17 $0.00 0.00% 1,552,833 $0.18 $0.18 $0.17
    28 Feb 2024 $0.18 $-0.01 -5.56% 1,405,689 $0.18 $0.18 $0.18
    27 Feb 2024 $0.18 $0.00 0.00% 1,130,816 $0.19 $0.19 $0.18
    26 Feb 2024 $0.18 $-0.01 -5.41% 1,337,113 $0.19 $0.19 $0.18
    23 Feb 2024 $0.19 $0.01 5.56% 1,440,692 $0.18 $0.19 $0.18
    22 Feb 2024 $0.18 $-0.01 -5.41% 1,593,189 $0.19 $0.19 $0.18
    21 Feb 2024 $0.19 $-0.01 -5.26% 4,850,338 $0.19 $0.19 $0.18
    20 Feb 2024 $0.19 $-0.01 -5.13% 2,405,610 $0.19 $0.20 $0.19
    19 Feb 2024 $0.20 $0.00 0.00% 1,291,115 $0.20 $0.20 $0.19
    16 Feb 2024 $0.20 $0.01 5.26% 2,188,045 $0.19 $0.20 $0.19
    15 Feb 2024 $0.19 $0.00 0.00% 733,103 $0.19 $0.19 $0.19
    14 Feb 2024 $0.19 $0.00 0.00% 911,289 $0.19 $0.19 $0.19
    13 Feb 2024 $0.19 $0.00 0.00% 1,689,702 $0.19 $0.20 $0.19
    12 Feb 2024 $0.19 $0.01 5.41% 1,449,847 $0.19 $0.20 $0.19
    09 Feb 2024 $0.19 $-0.01 -5.26% 671,798 $0.19 $0.19 $0.19
    08 Feb 2024 $0.19 $0.01 5.41% 1,365,297 $0.19 $0.19 $0.19
    07 Feb 2024 $0.19 $-0.01 -5.26% 2,185,447 $0.19 $0.20 $0.19
    06 Feb 2024 $0.19 $0.02 11.43% 5,960,977 $0.18 $0.20 $0.18
    05 Feb 2024 $0.18 $-0.01 -5.56% 2,345,501 $0.18 $0.18 $0.18
    02 Feb 2024 $0.18 $0.01 5.71% 610,603 $0.18 $0.18 $0.18
    01 Feb 2024 $0.18 $0.00 0.00% 1,007,804 $0.17 $0.18 $0.17

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    18 May 2023 Matthew (Matt) Callahan Exercise 1,166,667 $99,166
    Conversion of securities. 1,166,667 Performance Rights
    18 May 2023 Matthew (Matt) Callahan Buy 1,166,667 $99,166
    Conversion of securities.
    18 May 2023 H. William Bosch Exercise 500,000 $42,500
    Conversion of securities. 500,000 Performance Rights
    18 May 2023 H. William Bosch Buy 500,000 $42,500
    Conversion of securities.
    18 May 2023 Vince Ippolito Exercise 2,000,000 $170,000
    Conversion of securities. 2,000,000 Performance Rights
    18 May 2023 Vince Ippolito Buy 2,000,000 $170,000
    Conversion of securities.
    20 Mar 2023 Daniel Sharp Exercise 333,333 $32,333
    Conversion of securities. 666,667 Performance Rights
    20 Mar 2023 Daniel Sharp Buy 282,829 $27,434
    Exercise of options.
    20 Mar 2023 Daniel Sharp Exercise 1,000,000 $97,000
    Exercise of options.
    20 Mar 2023 Daniel Sharp Buy 333,333 $32,333
    Conversion of securities.
    20 Mar 2023 Vince Ippolito Exercise 2,000,000 $194,000
    Conversion of securities. 4,000,000 Performance rights
    20 Mar 2023 Vince Ippolito Buy 2,000,000 $194,000
    Conversion of securities.
    20 Mar 2023 Stewart Washer Transfer 321,551 $31,190
    Off-market transfer. Assuming off-market transfer of shares
    20 Mar 2023 Stewart Washer Buy 333,333 $32,333
    Conversion of securities.
    20 Mar 2023 Stewart Washer Exercise 333,333 $32,333
    Conversion of securities. 666,667 Performance Rights
    20 Mar 2023 Stewart Washer Transfer 321,551 $31,190
    Off-market transfer. Assuming off-market transfer of shares
    20 Mar 2023 H. William Bosch Exercise 500,000 $48,500
    Conversion of securities. 1,000,000 Performance Rights
    20 Mar 2023 H. William Bosch Buy 500,000 $48,500
    Conversion of securities.
    20 Mar 2023 Matthew (Matt) Callahan Buy 1,166,666 $113,166
    Conversion of securities.
    20 Mar 2023 Matthew (Matt) Callahan Exercise 1,166,666 $113,166
    Conversion of securities. 2,333,334 Performance Rights

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Matthew (Matt) Callahan Executive Director Feb 2020
    Mr Callahan is an experienced life sciences executive based in Philadelphia. He is a founder of Botanix and co-inventor of many of the Company's Permetrex enabled products. Mr Callahan was the founding CEO of Churchill Pharmaceuticals and developed Yonsa through FDA approval and subsequent sale to Sun Pharmaceuticals. He was also founding CEO of drug delivery company iCeutica Inc which developed 4 FDA approved products and was sold to US private equity investors. He has more than 25 years legal, IP and investment management experience.
    Dr Stewart James Washer Non-Executive Director Feb 2019
    Dr Washer has CEO and experience in medical biotech and cannabinoid companies. Dr Washer has held a number of board positions in the past, including chairman of Hatchtech Pty Ltd that was sold in 2015 for A$279m and was a director of iCeutica that was sold to US private equity investors. He was also a Senator with Murdoch University and was a director of AusBiotech Ltd.
    Dr H. William Bosch Executive Director Jul 2016
    Dr Bosch is an accomplished pharmaceutical executive with more than 30 years of experience and industry leadership in pharmaceutical R&D. Dr. Bosch served as CSO of iCeutica where he was the principal architect of SoluMatrix drug delivery technology, used in four FDA approved prescription drug products. Earlier in his career Dr. Bosch was a pioneer in the application of nanotechnology to pharmaceutical product development. He served as a co founder of NanoSystems LLC in 1995 and co-inventor of NanoCrystal Technology, leading to the successful development and FDA approval of seven prescription drug products for a variety of indications and routes of administration.
    Mr Vince Ippolito PresidentExecutive ChairmanExecutive Director May 2019
    Mr Ippolito has more than 30 years of experience in the pharmaceuticals industry, including over 20 years' experience in dermatology. He recently served as President and Chief Operating Officer of Dermavant Sciences, a biopharmaceutical company that is commercialising products which treat inflammatory skin diseases and medical dermatologic conditions. Mr Ippolito also sits on the Board of Suneva Medical, a privately held regenerative aesthetics company. Prior to his role at Dermavant Sciences, Mr Ippolito served as the Chief Commercial Officer and Executive Vice President of Anacor Pharmaceuticals, a dermatology-based biopharmaceutical company. During his time at Anacor he was responsible for building the marketing and sales functions, and developing the company's product portfolio, as well as playing a key role in the US$5.2bn sale to Pfizer. Earlier in his career, Mr Ippolito launched multiple new dermatology products during his tenure at Medicis Pharmaceutical Corporation, an industry-leading dermatology company. Mr. Ippolito served in multiple key executive roles, including Chief Commercial Officer, General Manager of Dermatology products, Senior Vice President of North American Sales and Executive Vice President, Sales and Marketing. Mr Ippolito played a key role in the sale of Medicis to Valeant for US$2.6bn in 2012 and he went on to serve as Senior Vice President, General Manager, Aesthetics
    Mr Daniel Sharp Non-Executive Director Mar 2022
    Mr Sharp is an investment banker with more than 30 years' experience in capital markets globally, advising the boards of technology and healthcare-based organisations. He also has a network of institutional and private wealth investors globally. Mr Sharp was a Corporate Finance Executive Director of Canaccord Genuity and has previously spearheaded the Corporate Finance departments at both Shaw and Partners and Lodge Partners.
    Ms Susan Patricia Park Company Secretary Apr 2023
    -
    Dr Howie McKibbon Chief Executive Officer Aug 2023
    -
    Howie McKibbon Chief Executive Officer
    -
    Susan Patricia Park Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    National Nominees Limited 139,690,538 9.83%
    Shenasaby Investments Pty Ltd <The Shenasaby A/C> 74,586,791 5.25%
    Caperi Pty Ltd <Caperi A/C> 52,573,784 3.70%
    Citicorp Nominees Pty Limited 51,527,974 3.63%
    Dr Henry William Bosch 18,836,702 1.33%
    Zenith Pacific Limited 17,972,222 1.26%
    Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 17,303,656 1.22%
    J P Morgan Nominees Australia Pty Limited 17,007,647 1.20%
    Hsbc Custody Nominees (Australia) Limited 16,843,169 1.19%
    Bnp Paribas Noms Pty Ltd <Drp> 14,818,037 1.04%
    Ubs Nominees Pty Ltd 14,148,149 1.00%
    Yarraandoo Pty Ltd <Yarraandoo Super Fund A/C> 13,000,000 0.91%
    Moffatt Investments Pty Ltd <Matthew Moffatt Family A/C> 10,560,000 0.74%
    Lightview Asset Pty Ltd 9,350,000 0.66%
    Zanya Nominees Pty Ltd<Jls Superannuation A/C> 8,984,545 0.63%
    Mr Vincent Peter Ippolito 8,801,644 0.62%
    Rollo Corp Property Holdings Pty Ltd <Rollo Corp Property A/C> 8,500,000 0.60%
    Mr Gary Charles Jones &Mrs Stephanie May Jones <G & S Jones Super Fund A/C> 8,000,000 0.56%
    343 Pty Ltd <343 Capital A/C> 7,125,667 0.50%
    Mr Stephane Nicolas Fayd Herbe <Fayd'Herbe Family A/C> 7,113,141 0.50%

    Profile

    since

    Note